SMARCA4失活及ARID1A/ARID1B共失活去分化子宫内膜癌临床前模型的建立与验证
研究将去分化子宫内膜癌(DDEC)手术样本植入免疫缺陷小鼠,建立PDX和细胞系模型,并对其组织学、免疫表型、遗传和表观遗传特征进行表征。三个模型均表现快速生长,两个PDX模型出现自发转移,PDX肿瘤保持亲本肿瘤特征。SMARCA4缺陷细胞系对GSK-J4显示低微摩尔敏感性,但相应PDX模型未见显著肿瘤生长抑制。
要点
- 成功建立三株DDEC患者来源模型,包括一株SMARCA4失活和两株ARID1A/ARID1B共失活模型。
- PDX肿瘤保持亲本肿瘤的未分化组织学、免疫表型及基因组和甲基化谱。
- SMARCA4缺陷细胞系对GSK-J4低微摩尔敏感,但PDX模型未见显著肿瘤生长抑制。
核心结论
- 建立的患者肿瘤来源模型准确再现DDEC特征,是有价值的临床前工具,有助于对该侵袭性肿瘤类型获得治疗见解。
研究设计与样本
- 将DDEC手术样本植入免疫缺陷小鼠,建立患者来源异种移植(PDX)模型和细胞系,并对患者肿瘤及所建PDX模型进行组织学、免疫表型、遗传和表观遗传特征表征。
主要发现
- 所有三个DDEC模型在体外和体内均表现快速生长,其中两个PDX模型在体内出现自发转移。
- PDX肿瘤保持与各自亲本肿瘤相同的未分化组织学和免疫表型,并具有相同的基因组和甲基化谱,包括一例MMR缺陷且SMARCA4基因组失活的DDEC和两例MMR缺陷且ARID1A与ARID1B均基因组失活的DDEC。
- SMARCA4缺陷细胞系对GSK-J4显示低微摩尔敏感性,但在相应PDX模型中未观察到显著肿瘤生长抑制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dedifferentiated endometrial cancer (DDEC) is an uncommon and clinically highly aggressive subtype of endometrial cancer characterized by genomic inactivation of SWItch/Sucrose Non-Fermentable (SWI/SNF) complex protein. It responds poorly to conventional systemic treatment and its rapidly progressive clinical course limits the therapeutic windows to trial additional lines of therapies. This underscores a pressing need for biologically accurate preclinical tumor models to accelerate therapeutic development. METHODS: DDEC tumor from surgical samples were implanted into immunocompromised mice for patient-derived xenograft (PDX) and cell line development. The histologic, immunophenotypic, genetic and epigenetic features of the patient tumors and the established PDX models were characterized. The SMARCA4-deficienct DDEC model was evaluated for its sensitivity toward a KDM6A/B inhibitor (GSK-J4) that was previously reported to be effective therapy for other SMARCA4-deficient cancer types. RESULTS: All three DDEC models exhibited rapid growth in vitro and in vivo, with two PDX models showing spontaneous development of metastases in vivo. The PDX tumors maintained the same undifferentiated histology and immunophenotype, and exhibited identical genomic and methylation profiles as seen in the respective parental tumors, including a mismatch repair (MMR)-deficient DDEC with genomic inactivation of SMARCA4, and two MMR-deficient DDECs with genomic inactivation of both ARID1A and ARID1B. Although the SMARCA4-deficient cell line showed low micromolecular sensitivity to GSK-J4, no significant tumor growth inhibition was observed in the corresponding PDX model. CONCLUSIONS: These established patient tumor-derived models accurately depict DDEC and represent valuable preclinical tools to gain therapeutic insights into this aggressive tumor type.
引用
- Wong NKY, Llaurado Fernandez M, Kommoss FKF, et al. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma. Gynecol Oncol. 2023. PMID: 37556934. doi:10.1016/j.ygyno.2023.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。